These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 21103667)

  • 41. Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.
    Spinler SA
    Am J Manag Care; 2009 Mar; 15(2 Suppl):S42-7. PubMed ID: 19355808
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High on treatment platelet reactivity and stent thrombosis.
    Rajendran S; Parikh D; Shugman I; French JK; Juergens CP
    Heart Lung Circ; 2011 Aug; 20(8):525-31. PubMed ID: 21592858
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
    James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
    Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clopidogrel: the data, the experience, and the controversies.
    Sadanandan S; Singh IM
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):361-74. PubMed ID: 23057989
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Thienopyridine antiplatelet agents: focus on prasugrel.
    Freeman MK
    Consult Pharm; 2010 Apr; 25(4):241-57. PubMed ID: 20511177
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Non-cardiac surgery in patients with coronary stents: the RECO study.
    Albaladejo P; Marret E; Samama CM; Collet JP; Abhay K; Loutrel O; Charbonneau H; Jaber S; Thoret S; Bosson JL; Piriou V
    Heart; 2011 Oct; 97(19):1566-72. PubMed ID: 21791513
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents.
    Butler MJ; Eccleston D; Clark DJ; Ajani AE; Andrianopoulos N; Brennan A; New G; Black A; Szto G; Reid CM; Yan BP; Shaw JA; Dart AM; Duffy SJ;
    Am Heart J; 2009 May; 157(5):899-907. PubMed ID: 19376319
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antiplatelet therapy after percutaneous coronary intervention.
    Holmes DR
    Cerebrovasc Dis; 2006; 21 Suppl 1():25-34. PubMed ID: 16479099
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    Aronow HD; Steinhubl SR; Brennan DM; Berger PB; Topol EJ;
    Am Heart J; 2009 Feb; 157(2):369-74. PubMed ID: 19185647
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents.
    Baber U; Akhter M; Kothari S; Sharma SK; Kini A
    J Invasive Cardiol; 2010 Feb; 22(2):80-3. PubMed ID: 20124594
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Significant gastrointestinal bleeding in patients at risk of coronary stent thrombosis.
    Dai X; Makaryus AN; Makaryus JN; Jauhar R
    Rev Cardiovasc Med; 2009; 10(1):14-24. PubMed ID: 19367228
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP.
    Moerenhout CM; Claeys MJ; Haine S; Miljoen H; Bosmans JM; Vertessen F; Kluppels K; Van der Planken M; Vrints CJ
    Am Heart J; 2010 Mar; 159(3):434-8. PubMed ID: 20211306
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
    Wiviott SD
    Cardiol Clin; 2008 Nov; 26(4):629-37. PubMed ID: 18929236
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Beware of being caught on the rebound.
    Lordkipanidzé M; Harrison P
    J Thromb Haemost; 2011 Jan; 9(1):21-3. PubMed ID: 21210949
    [No Abstract]   [Full Text] [Related]  

  • 57. Antiplatelet therapy in ENT surgery: a review.
    Sylvester DC; Coatesworth AP
    J Laryngol Otol; 2012 Apr; 126(4):331-6. PubMed ID: 22182587
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clopidogrel cessation triggers aspirin rebound in patients with coronary stent.
    Djukanovic N; Todorovic Z; Obradovic S; Njegomirovic S; Zamaklar-Trifunovic D; Protić D; Ostojic M
    J Clin Pharm Ther; 2014 Feb; 39(1):69-72. PubMed ID: 24286218
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clopidogrel "resistance": where are we now?
    Qureshi Z; Hobson AR
    Cardiovasc Ther; 2013 Feb; 31(1):3-11. PubMed ID: 21884029
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recurrent acute stent thrombosis due to allergic reaction secondary to clopidogrel therapy.
    Karabay CY; Can MM; Tanboğa IH; Ahmet G; Bitigen A; Serebruany V
    Am J Ther; 2011 Jul; 18(4):e119-22. PubMed ID: 20683245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.